DNA Nanodevice Cancer Vaccine Delivers Peptide Antigens to Achieve 80% Complete Tumor Regression in Mice
A programmable DNA nanodevice that precisely delivers and controllably releases peptide tumor antigens achieved 80% complete tumor regression in mice and prevented melanoma lung metastases.
Quick Facts
What This Study Found
A DNA nanodevice carrying peptide neoantigens achieved remarkable results in mouse cancer models. In the B16-OVA melanoma model, it inhibited tumor growth by 50%. Even more impressively, when loaded with tumor-specific neoantigens for MC-38 colorectal cancer, it induced complete tumor regression in 80% of mice.
The key innovation is a sulfonium-based bio-orthogonal chemistry that enables reversible attachment and controlled release of antigen peptides from the DNA scaffold. The nanodevice was effectively internalized by antigen-presenting cells, enhanced cytokine secretion (TNF-α, IL-6, IL-12), stimulated antigen-specific CD8+ killer T cells, and significantly prevented lung metastases of melanoma when combined with CpG adjuvant.
Key Numbers
50% melanoma growth inhibition (B16-OVA model) · 80% complete tumor regression (MC-38 neoantigen model) · enhanced TNF-α, IL-6, IL-12 cytokines · antigen-specific CD8+ T cell response · prevented lung metastases · stable in serum · effective antigen-presenting cell uptake
How They Did This
Researchers created peptide-nucleic acid conjugates using propargyl sulfonium-based bio-orthogonal chemistry, which enables reversible peptide attachment under mildly alkaline conditions. The conjugates were folded into DNA nanodevice scaffolds. In vitro testing used RAW264.7 macrophages and bone marrow-derived dendritic cells (BMDCs) to assess internalization and immune activation. In vivo experiments used C57BL mice with B16-OVA melanoma (with OVA model antigen and CpG adjuvant) and MC-38 colorectal tumors (with tumor-specific neoantigen).
Why This Research Matters
Personalized cancer vaccines that train the immune system to attack tumors based on their unique mutations (neoantigens) are one of the most promising frontiers in oncology. But delivering peptide antigens effectively to immune cells remains a major challenge. This DNA nanodevice solves the delivery problem with programmable precision — each antigen peptide is at a defined position with calculable dosage. The 80% complete tumor regression rate is exceptional for a vaccine-alone approach and demonstrates the potential of precise peptide antigen delivery for personalized cancer immunotherapy.
The Bigger Picture
Personalized neoantigen vaccines are among the most anticipated developments in cancer immunotherapy, with companies like BioNTech and Moderna racing to develop them. The challenge is not just identifying the right peptide antigens — it's delivering them effectively to the immune system. This DNA nanodevice approach offers programmable, precise delivery with built-in dosage control. Combined with the mRNA vaccine revolution, peptide neoantigen delivery platforms like this could form the basis of next-generation personalized cancer treatments.
What This Study Doesn't Tell Us
All experiments were in mice, and mouse immune responses to cancer vaccines often don't predict human outcomes. The 80% complete regression was in a specific mouse tumor model (MC-38) that is relatively immunogenic. Human tumors are more heterogeneous and immunosuppressive. Manufacturing personalized DNA nanodevice vaccines for individual patients presents significant scale-up and cost challenges. Long-term immunity and memory responses were not assessed.
Questions This Raises
- ?Can this DNA nanodevice platform be manufactured quickly enough for personalized cancer treatment, where each patient needs a unique vaccine?
- ?How would this approach perform in combination with checkpoint inhibitors like anti-PD-1 therapy?
- ?Will the 80% complete regression rate translate to meaningful clinical responses in human solid tumors, which are typically more immune-resistant?
Trust & Context
- Key Stat:
- 80% complete tumor regression In a mouse colorectal cancer model, the DNA nanodevice vaccine carrying tumor-specific neoantigen peptides caused complete tumor disappearance in 80% of treated mice
- Evidence Grade:
- This study is graded as preliminary. While the results are exceptional (80% complete regression), all data comes from mouse tumor models. Published in ACS Nano (high impact), the science is rigorous but the gap between mouse cancer models and human clinical outcomes is substantial.
- Study Age:
- Published in 2022, this study is relatively recent and contributes to the rapidly advancing field of neoantigen-based cancer vaccines and programmable nanomedicine.
- Original Title:
- Sulfonium-Driven Neoantigen-Released DNA Nanodevice as a Precise Vaccine for Tumor Immunotherapy and Prevention.
- Published In:
- ACS nano, 16(11), 19509-19522 (2022)
- Authors:
- Zhang, Yaping(3), Xu, Hongkun, Jiang, Leying(2), Liu, Zhaodi, Lian, Chenshan, Ding, Xiaofeng, Wan, Chuan, Liu, Na, Wang, Yuena, Yu, Zhiqiang, Zhu, Lizhi, Yin, Feng, Li, Zigang
- Database ID:
- RPEP-06648
Evidence Hierarchy
Frequently Asked Questions
What is a neoantigen cancer vaccine?
Every tumor has unique mutations that produce abnormal proteins not found in normal cells. Small fragments of these proteins — called neoantigens — can be used to train the immune system to recognize and attack the tumor. A neoantigen vaccine delivers these peptide fragments to immune cells, essentially teaching the body to fight its own specific cancer. This approach is personalized: each patient's vaccine is designed based on their tumor's unique mutations.
What makes this DNA nanodevice approach different from other cancer vaccines?
Most vaccine delivery systems randomly distribute antigen peptides, making it hard to control exactly how much each immune cell receives. The DNA nanodevice positions each peptide at a precise location on a programmable scaffold, allowing exact dosage calculation. It also uses a clever chemical linkage (sulfonium-based) that holds peptides tightly during delivery but releases them once inside immune cells, ensuring the antigen is presented at the right time and place to trigger a strong immune response.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-06648APA
Zhang, Yaping; Xu, Hongkun; Jiang, Leying; Liu, Zhaodi; Lian, Chenshan; Ding, Xiaofeng; Wan, Chuan; Liu, Na; Wang, Yuena; Yu, Zhiqiang; Zhu, Lizhi; Yin, Feng; Li, Zigang. (2022). Sulfonium-Driven Neoantigen-Released DNA Nanodevice as a Precise Vaccine for Tumor Immunotherapy and Prevention.. ACS nano, 16(11), 19509-19522. https://doi.org/10.1021/acsnano.2c09708
MLA
Zhang, Yaping, et al. "Sulfonium-Driven Neoantigen-Released DNA Nanodevice as a Precise Vaccine for Tumor Immunotherapy and Prevention.." ACS nano, 2022. https://doi.org/10.1021/acsnano.2c09708
RethinkPeptides
RethinkPeptides Research Database. "Sulfonium-Driven Neoantigen-Released DNA Nanodevice as a Pre..." RPEP-06648. Retrieved from https://rethinkpeptides.com/research/zhang-2022-sulfoniumdriven-neoantigenreleased-dna-nanodevice
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.